Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus
- PMID: 8268341
- DOI: 10.1093/clinids/17.4.625
Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus
Abstract
We describe two cases of visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV); both cases were resistant to antimony compounds but were cured with liposomal amphotericin B, with no significant toxicity. A review of the previous reported cases of antimony-resistant visceral leishmaniasis in HIV-infected patients confirmed the effectiveness of treatment with liposomal amphotericin B, which directly targets infected macrophages and reaches high levels in plasma and tissue.
Comment in
-
Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B.Clin Infect Dis. 1994 Sep;19(3):560. doi: 10.1093/clinids/19.3.560. Clin Infect Dis. 1994. PMID: 7811891 No abstract available.
-
Visceral leishmaniasis following treatment with liposomal amphotericin B.Clin Infect Dis. 1994 Aug;19(2):362. doi: 10.1093/clinids/19.2.362. Clin Infect Dis. 1994. PMID: 7986926 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
